JNJ - Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial | Benzinga

Wednesday, Johnson & Johnson (NYSE:JNJ) announced topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms.

Seltorexant is an investigational first-in-class selective antagonist of the human orexin-2 receptor being studied for the adjunctive treatment of MDD with insomnia symptoms.

Also Read: Johnson & Johnson's Bankruptcy Tactics Are Fraudulent, Plaintiffs Accuse Company Of Defrauding Cancer Victims.

The findings will be presented at ...

Full story available on Benzinga.com